TOP TEN perturbations for Q8NHB7 (Homo sapiens)
Organism: Homo sapiens
Gene: Q8NHB7
Selected probe(set): 1567288_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of Q8NHB7 (1567288_at) across 5610 perturbations tested by GENEVESTIGATOR:
HIV-associated neurocognitive disorder study 2 (HIVE) / normal genu sample
Relative Expression (log2-ratio):0.5701432Number of Samples:2 / 8
| Experimental | HIV-associated neurocognitive disorder study 2 (HIVE) |
| Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with HIV encephalitis (HIVE). The patients received an antiretroviral therapy (ART). | |
| Control | normal genu sample |
| Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from healthy subjects. |
medulloblastoma study 2 / non-tumor brain tissue
Relative Expression (log2-ratio):0.5542731Number of Samples:4 / 9
| Experimental | medulloblastoma study 2 |
| Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma. | |
| Control | non-tumor brain tissue |
| Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor. |
HIV-associated neurocognitive disorder study 5 (minimal) / HIV-associated neurocognitive disorder study 4 (minimal)
Relative Expression (log2-ratio):-0.48791456Number of Samples:6 / 2
| Experimental | HIV-associated neurocognitive disorder study 5 (minimal) |
| Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with minimal histopathological changes including trivial microscopic abnormalities, atherosclerosis and minimal perivascular inflammation. The patients received an antiretroviral therapy (ART). | |
| Control | HIV-associated neurocognitive disorder study 4 (minimal) |
| Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with minimal histopathological changes including trivial microscopic abnormalities, atherosclerosis and minimal perivascular inflammation. The patients did not receive any antiretroviral therapy (ART). |
HIF-1a depletion study 2 (normoxia; AB81) / control AB81 cell sample (normoxia)
Relative Expression (log2-ratio):0.46053314Number of Samples:3 / 3
| Experimental | HIF-1a depletion study 2 (normoxia; AB81) |
| Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a (Hypoxia-inducible factor 1-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. | |
| Control | control AB81 cell sample (normoxia) |
| Human podocyte cell line AB81 treated with normoxia (20% O2) for 24 hours. Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. |
bucetin study 2 (300uM) / vehicle (DMSO) treated hepatocyte sample
Relative Expression (log2-ratio):0.43741322Number of Samples:2 / 2
| Experimental | bucetin study 2 (300uM) |
| Hepatocytes treated with compound: bucetin (300uM; CHEMBL1697856) for 24 hours. ATC code: | |
| Control | vehicle (DMSO) treated hepatocyte sample |
| Hepatocytes treated with vehicle (DMSO) for 24 hours. |
asthma study 28 / normal alveolar macrophage sample
Relative Expression (log2-ratio):-0.4288311Number of Samples:15 / 15
| Experimental | asthma study 28 |
| Alveolar macrophages obtained from patients with asthma by bronchoscopy with bronchoalveolar lavage after pre-treatment with 360mcg albuterol. Macrophages were sorted by flow cytometry using forward scatter and autofluorescence characteristics to 98 ± 2% purity. All subjects had lower lung function than healthy control donors. Subject inclusion criteria: age 18 to 70, non-smokers, a physician diagnosis of asthma, use of only inhaled beta-agonist medications for therapy and at least one of the following: a) asthma symptoms on ≥ 2 days/week, b) beta-agonist use on on ≥ 2 days/week, or c) FEV1 < 85% of predicted. Exclusion criteria: inhaled corticosteroids or leukotriene antagonists use. Subject characteristics: age 35 ± 10 years, FEV1 prebronchodilator 81 ± 15% predicted, FEV1/FVC prebronchodilator 0.7 ± 0.11, FEV1 post-bronchodilator 91 ± 12% predicted, FEV1/FVC post-bronchodilator 0.77 ± 0.09 (mean ± SD), PC20, mg/dl methacholine 0.5 (0.06, 1.2) (median (interquartile range)). | |
| Control | normal alveolar macrophage sample |
| Alveolar macrophages obtained from non-smoking healthy donors by bronchoscopy with bronchoalveolar lavage after pre-treatment with 360mcg albuterol. Macrophages were sorted by flow cytometry using forward scatter and autofluorescence characteristics to 98 ± 2% purity. Subject inclusion criteria: age 30 to 65 years, no history of lung disease and a history of <10 pack-years of smoking with no smoking in the previous 10 years. Subject characteristics: age 41 ± 8 years, FEV1 prebronchodilator 104 ± 12% predicted, FEV1/FVC prebronchodilator 0.80 ± 0.06, FEV1 post-bronchodilator 107 ± 12% predicted, FEV1/FVC post-bronchodilator 0.83 ± 0.05 (mean ± SD), PC20, mg/dl methacholine 64 (64, 64) (median (interquartile range)). |
acesulfame K study 1 (24h) / vehicle (DMSO) treated HepG2 cell sample
Relative Expression (log2-ratio):0.41611385Number of Samples:3 / 7
| Experimental | acesulfame K study 1 (24h) |
| HepG2 cells exposed to 2mM acesulfame K in DMSO solvent for 24 hours. ATC code:--- | |
| Control | vehicle (DMSO) treated HepG2 cell sample |
| HepG2 cells exposed to DMSO solvent for 24 hours. |
stem cell differentiation study 47 (BMP-2; IBMX; 2d) / stem cell differentiation study 47 (BMP-2; TGFb; 2d)
Relative Expression (log2-ratio):0.41519117Number of Samples:3 / 3
| Experimental | stem cell differentiation study 47 (BMP-2; IBMX; 2d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 2 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 2 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (BMP-2; TGFb; 2d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 2 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 2 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |
polymyositis study 1 / inclusion body myositis study 1
Relative Expression (log2-ratio):0.40656567Number of Samples:5 / 5
| Experimental | polymyositis study 1 |
| Biceps femoris biopsy muscle samples from patients with clinical diagnosis of polymyositis (PM). | |
| Control | inclusion body myositis study 1 |
| Biceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM). |
glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):-0.38886642Number of Samples:2 / 4
| Experimental | glioma study 17 (glioblastoma; unsorted) |
| Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. | |
| Control | non-tumor cortical tissue |
| Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |